Panaxia is making significant strides in medical cannabis research and development. The company is investing heavily in the field, with a focus on creating high-quality, evidence-based products.
Their research efforts are led by a team of experienced scientists and clinicians who are working to advance our understanding of cannabis and its potential therapeutic applications. This expertise is crucial for developing effective treatments.
Panaxia is committed to producing products that meet the highest standards of quality and safety. They are working to ensure that their products are not only effective but also reliable and consistent.
By advancing medical cannabis research and development, Panaxia is helping to pave the way for better treatments and a deeper understanding of this complex plant.
Take a look at this: What Does Mou Stand for in Business
Research and Development
Panaxia has been actively conducting clinical trials to evaluate the effectiveness and safety of their medical cannabis products.
One notable trial was conducted in January 2019, where Panaxia tested the bioavailability and safety of sublingual medical cannabis tablets.
The trial was a first of its kind, and its results were promising, showing excellent efficacy of absorption in the blood and safety of the tablets.
Panaxia also conducted a clinical trial in February 2019 to evaluate the bioavailability of administration of medical cannabis through a metered-dose inhaler.
The inhaler uses a vaporizer and precise dose of cannabis extract, ensuring a more precise and reproducible intake than smoking.
Here's a summary of the clinical trials conducted by Panaxia:
- Sublingual medical cannabis tablets: evaluated bioavailability and safety (January 2019)
- Metered-dose inhaler: evaluated bioavailability of administration through a vaporizer (February 2019)
- Leading products: reported excellent results with high absorption rate and low variance compared to Sativex (December 2019)
Research
Research has been a crucial aspect of Panaxia's journey. They've been pushing the boundaries of medical cannabis administration.
In January 2019, Panaxia announced a trial for registration with the Israeli Ministry of Health to evaluate the bioavailability and safety of their sublingual medical cannabis tablets. This was a significant step forward in treating chronic pain.
Their medical cannabis products, marketed by Rafa, are being evaluated in a clinical study. The results of this trial will pave the way for a revolution in treatment with medical cannabis.
Readers also liked: Virtual Debit Card for Free Trial
Panaxia's clinical trial aimed to assess the safety and efficacy of their sublingual tablets. The trial proved that their products have a higher absorption rate and lower variance than Sativex, the industry's gold standard.
Here are some key findings from Panaxia's clinical trial:
- Sublingual tablets have a higher absorption rate than Sativex.
- Sublingual tablets have lower variance than Sativex.
- Tablets, suppositories, and inhaled cannabis extract all proved to be safe and effective.
In February 2019, Panaxia announced another clinical trial to evaluate the bioavailability of medical cannabis through a metered-dose inhaler. This innovative device uses a vaporizer to deliver a precise dose of cannabis extract.
By December 2019, Panaxia reported excellent results from their clinical trials. Their products proved to be safe and effective, with a high absorption rate and low variance. This is a significant breakthrough in the field of medical cannabis.
For more insights, see: September 2019 Events in the U.S. Repo Market
International Partnerships
Panaxia Pharmaceuticals is expanding its reach through international partnerships. They've signed a deal with Neuraxpharm, a leading European company specializing in disorders of the central nervous system.
This collaboration is similar to those seen in Germany, where foreign companies partner with established medical products providers to enter the market. Panaxia is the only Israeli company with EU-GMP certification for the production of medical cannabis products.
They're planning to establish a manufacturing entity in France, with the goal of commercial production and distribution of their cannabinoid medicinal products. As part of this collaboration, Panaxia and Neuraxpharm are already planning to respond to the tender issued by the French government and medications agency ANSM.
The French trial, which is set to begin by the first quarter of March 2021, will involve a 3,000 person trial. Participating companies will need to participate for free, rather than importing products from another country and charging high prices.
Curious to learn more? Check out: Nvidia-backed Coreweave Is Planning an Ipo in 2025.
Featured Images: pexels.com
